Tiziana Life Sciences is trading at $1.04, up 9.05%, in pre-market on September 30, 2026, with no clear company-specific catalyst identified. - September 29 close: $0.95. - On September 28, the first three participants received their first dose in the Phase 2a BANYAN ALS trial of intranasal foralumab; evidence does not establish the announcement as the cause. - Broader index futures were modestly higher, but the provided context showed no same-direction move above 0.5% clearly explaining the gain.